Clinical Trials Directory

Trials / Unknown

UnknownNCT00192673

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
85 (estimated)
Sponsor
Nordic Society for Pediatric Hematology and Oncology · Academic / Other
Sex
All
Age
1 Year – 14 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is 1. to determine the correct dose for intramuscular administration 2. to compare the frequency of antibody formation after intramuscular administration of native E.coli asparaginase and PEG-asparaginase during two treatment courses in the treatment of childhood lymphoblastic leukemia

Detailed description

Asparaginase is used in the treatment of childhood lymphoblastic leukemia. Approximately 1/3 of the patients develops blocking antibodies against native E.coli asparaginase during the second exposure, so that they do not benefit from treatment and thus may have a worse prognosis. PEG-asparaginase is less immunogenic so that fewer patients may develop antibodies during the second exposure. There is no published study about the antibody formation after treatment of children with PEG-asparaginase during two treatment courses. The first part of the study is a description of the pharmacokinetics of PEG-asparaginase after intramuscular administration in order to determine the correct dose. The second part of the study is a comparison of antibody formation during two treatment courses after intramuscular administration og native E.coli asparaginase and PEG-asparaginase. Other side effects than antibodies will be registered during treatment with PEG-asparaginase. Finally comparison of the 5-year EFS between the groups (native E.coli asparaginase and PEG-asparaginase as well as patients who have and have not developed antibodies) will be evaluated.

Conditions

Interventions

TypeNameDescription
DRUGPEG-asparaginase

Timeline

Start date
2005-06-01
Completion
2013-12-01
First posted
2005-09-19
Last updated
2009-09-30

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00192673. Inclusion in this directory is not an endorsement.